Focused on rare genetic and aging-related disorders, the company is advancing NB4168, a highly bioavailable NAD+ precursor, for ataxia telangiectasia. Strong clinical evidence, a robust patent portfolio, and a platform strategy position it for premium rare disease market opportunities.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.